Thoughts of Experience

I would like to discuss the trends in the aesthetic industry over the last 25 years in Australia. The pros and cons of advances in this hi technology and risky world.

Because I have been in the field since 1998, I have seen the whole arc firsthand.

My sense is that the Australian aesthetic industry has moved through three big eras:

1998 to mid-2000s: a more clinician-led, procedure-led world. Cosmetic medicine was far less mainstream, treatments were less “consumerised,” and the field was more tightly associated with surgery, resurfacing, peels, and early-generation lasers. Botulinum toxin and fillers were growing, but the industry still felt more medical than retail.

Late 2000s to 2010s: the non-surgical boom. Injectables, energy devices, body contouring, threads, and “lunchtime procedures” changed the market. Globally, non-surgical aesthetics expanded sharply over the last decade; ISAPS reports a massive global shift towards non surgical procedures with injectables still the largest category, with injectables still the largest category. In Australia, Ahpra has described the non-surgical sector as a booming industry worth more than A$1 billion a year.

2020s: the digital-commercial phase. Social media, influencer culture, imaging, remote consultation models, device marketing, and now AI-assisted analysis have pushed aesthetics further toward a high-volume, high-visibility marketplace. That growth has been strong enough that regulators have responded with major reforms: tighter cosmetic surgery rules from July 2023, protection of the title “surgeon” from September 2023, TGA restrictions on how cosmetic injectables can be referenced in advertising, and new non-surgical cosmetic procedure guidelines that took effect on 2 September 2025.

From a practitioner’s point of view, the good trends are real.

The first is better technology and better outcomes. Fractional, hybrid, and non-ablative lasers have improved precision and reduced downtime compared with older resurfacing approaches, while newer imaging and assessment tools can make treatment planning more consistent and personalised. Reviews of laser technology specifically note the move toward fractional and hybrid systems with less recovery time and broader utility. Recent AI reviews also describe more objective skin analysis, treatment simulation, and personalised planning.

The second is less invasive care. Many patients can now achieve meaningful improvement without surgery, general anaesthesia, or long recovery. That has widened access and allowed earlier, more conservative intervention. The Medical Board’s current definition of non-surgical cosmetic procedures spans injectables, thread lifts, CO2 laser resurfacing, cryolipolysis, laser hair removal, dermabrasion, chemical peels, and hair transplants, which shows how broad and sophisticated this category has become.

The third is more considered aesthetic thinking. The field has shifted from simply “filling lines” to full-face assessment, skin quality, texture, collagen stimulation, and combination treatments. In the best hands, the industry is now more individualised, more anatomically informed, and often more natural-looking than it was 20 years ago.

The fourth is greater emphasis on safety and governance — at least now. Australia’s reforms are significant: cosmetic surgery patients now require GP referral, the title “surgeon” is legally protected, and the newer non-surgical rules stress training, patient welfare before profit, and stronger protections for younger patients, including a seven-day cooling-off period for under-18s.

But the worrying trends are just as real, and I suspect these are the ones you’ve felt most strongly.

The biggest one is the retailisation of medicine. Aesthetics has moved from a consultation-driven model toward a consumer model in parts of the market. Ahpra’s own public explanation for the 2025 non-surgical guidelines lists problems such as unclear practitioner qualifications, advertising that minimises risk, upselling, financial gain competing with patient wellbeing, and high numbers of young and potentially vulnerable people seeking procedures. That is a very telling regulatory diagnosis of where the industry drifted.

The second is the dangerous myth that non-surgical means low-risk. It does not. TGA explicitly treats most cosmetic injectables as prescription-only medicines that cannot be advertised to the public, and Ahpra now states plainly that these are clinical procedures, not beauty services. The complication literature backs that up: filler vascular occlusion is uncommon but can cause necrosis, blindness, and stroke; vision loss, while rare, can be devastating and often irreversible. Even technologies perceived as gentler, like fractional laser resurfacing, can produce significant complications, especially in higher-risk patients or darker phototypes.

The third is expansion creep. As profit and demand increased, more practitioners and businesses were drawn into the space. Ahpra’s 2025 reforms specifically say many practitioners will need more education before expanding into non-surgical cosmetic procedures, and that for some professions these procedures remain outside expansion unless additional competence is established. That is effectively a regulator saying the market expanded faster than training standards did.

The fourth is social-media distortion. Advertising and online content have changed patient psychology. Faster demand generation, before-and-after culture, filters, influencer endorsements, and “preventative” messaging have all blurred the line between informed choice and manufactured insecurity. Australia’s newer cosmetic advertising rules were written precisely because regulators judged that cosmetic advertising can exploit vulnerability, trivialise risk, and create unrealistic expectations.

The fifth is AI’s double edge. AI and digital imaging can improve objectivity, documentation, and patient education, but they can also create false precision. Reviews note ethical concerns around algorithmic bias, privacy, and unrealistic simulations. Results may less accurate on different skin tones if the training data is not diverse enough more broadly, performance can drop on diverse skin tones when training data are not representative. In aesthetics, that means AI may help planning, but it should never be allowed to overpower clinical judgment or substitute for deep experience.

So if I had to summarise the last 25 years in one sentence, I’d put it this way:

The science and technology have advanced significantly but the commercial side has not kept pace with the same level of maturity.

That is probably why many experienced clinicians feel both proud and uneasy:

• proud because outcomes, comfort, recovery, and sophistication are far better than in 1998
• uneasy because the sector has become faster, louder, younger, more sales-driven, and in some corners less respectful of risk

In Australia, the recent reforms are almost an official acknowledgment of those concerns. Regulators are saying, in effect: this is medicine, not merchandising.